Virus 20structure 20for 20website 2019
Senecalogo 2

Seneca Therapeutics, Inc (STI)

STI is developing Seneca Valley Virus (SVV-001) for solid cancer indications, a Phase II ready and best in class high value oncolytic immunotherapeutic.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded February 2018
  • Employees 4
  • Incorporation Type C-corp
  • Website senecatherapeutics.com

Company Summary

STI is developing SVV for cancer treatment, the clinically tested best in class oncolytic virus (OV) immunotherapeutic based on 3 key values; OV are one of the most promising areas in cancer therapy today because they dramatically enhance the patient benefit of checkpoint inhibitors; OV companies are being acquired at high valuations; and STI is ready for Ph II trials in humans having promising Ph I/II data, an active IND and GMP clinical lot.

Team

  • 2019 06 17
    President and Chief Executive Officer

    Dr. Hallenbeck is the Founder, President and CEO of Seneca. He is a multiple award winning, serial entrepreneur, with 27 years in the biotechnology industry with expertise in all phases of cancer immuno-therapeutics R&D. As the sole founder of Neotropix, raised $30M in VC, then successfully led SVV (NTX-001) through IND approval, and completed a Phase I/II clinical trial, establishing an excellent safety record & compelling evidence of efficacy.

  • 74122c1c c9ea 4516 b6e5 2287a247816d
    Chief Financial Officer

    Ben is a successful financial and operating management expert in due diligence, profitability analysis and improvement, cash flow management, equity financing, as well as systems selection and implementation. As an advisory board member of Mid-Atlantic Diamond Ventures, he is an invaluable mentor for many high growth investment deals. He performs due diligence for early stage investors & prepares and executes corporate financial transactions.

  • 8123dd42 57d6 42aa 9116 e5918839ff31
    Vice President of Manufacturing

    Dr. Wechuck is a biochemical engineer with 15 yrs of experience in recombinant protein production, viral vector manufacturing, and biologics testing. He has developed and advanced the proprietary cGMP manufacturing production, purification, and formulation methodologies for Type 1 Diabetes Drug Products and viral vectors for gene therapy products. He has led CMC regulatory elements for several investigational drug applications in the US & Europe.

  • B9817a2f 7e24 4ffe 98d7 2b06be29f727
    Chief Medical Officer

    Dr. Sankar is President & Founder of SwanBio, LLC, a BD & Clinical Strategy consultancy firm that facilitates the translation of scientific discoveries into cancer therapeutics. An expert in global clinical development and regulatory strategies for therapeutic drugs; he has led numerous clinical trials in oncology therapy ranging from breast, ovarian, pancreatic, liver, lung, and connective tissue tumors, to a range of hematological malignancies.

  • 450a724f 77f3 491b a785 b9cd9adb39db
    Director of R&D

    Dr, Chada's drug development expertise includes antibodies, cell and gene therapies and small molecules for oncology, genetic diseases and immunotherapy. He is an expert in translating product concepts into clinical trials: >15 INDs; >20 Phase I-III. Dr. Chada is an adjunct faculty member in Dept. Experimental Therapeutics at MD Anderson Cancer Center. He is also a special advisor to the chief scientific officer of MDACC Moonshots Initiative.